{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:41:38Z","timestamp":1780393298764,"version":"3.54.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K21715"],"award-info":[{"award-number":["JP20K21715"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K21715"],"award-info":[{"award-number":["JP20K21715"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"DOI":"10.1186\/s12877-025-05982-x","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T09:35:10Z","timestamp":1746783310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying suppressive factors of Alzheimer\u2019s disease through comprehensive analysis of real-world data: a single-center retrospective study"],"prefix":"10.1186","volume":"25","author":[{"given":"Mana","family":"Shiotani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hyohdoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kazui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyasu","family":"Okuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"5982_CR1","unstructured":"Alzheimer\u2019s Disease International. World Alzheimer report 2022. 2022. https:\/\/www.alzint.org\/resource\/world-alzheimer-report-2022\/. Accessed 30 Jul 2024."},{"key":"5982_CR2","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3389\/fphar.2019.01045","volume":"10","author":"Y Ohno","year":"2019","unstructured":"Ohno Y, Kunisawa N, Shimizu S. Antipsychotic treatment of behavioral and psychological symptoms of dementia (BPSD): management of extrapyramidal side effects. Front Pharmacol. 2019;10:1045.","journal-title":"Front Pharmacol"},{"key":"5982_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11920-019-1049-5","volume":"21","author":"LJ Bessey","year":"2019","unstructured":"Bessey LJ, Walaszek A. Management of behavioral and psychological symptoms of dementia. Curr Psychiatry Rep. 2019;21:66.","journal-title":"Curr Psychiatry Rep"},{"key":"5982_CR4","doi-asserted-by":"crossref","unstructured":"2021 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2021;17:327\u2013406.","DOI":"10.1002\/alz.12328"},{"key":"5982_CR5","unstructured":"Alzheimer\u2019s Disease International. World Alzheimer report 2021. 2021. https:\/\/www.alzint.org\/resource\/world-alzheimer-report-2021\/. Accessed 30 Jul 2024."},{"key":"5982_CR6","unstructured":"Statistics Bureau, Ministry of Internal Affairs and Communications of Japan. Statistical handbook of Japan 2022. 2022. https:\/\/www.stat.go.jp\/english\/data\/handbook\/pdf\/2022all.pdf. Accessed 30 Jul 2024."},{"key":"5982_CR7","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12877-021-02540-z","volume":"21","author":"N Nakahori","year":"2021","unstructured":"Nakahori N, Sekine M, Yamada M, Tatsuse T, Kido H, Suzuki M. Future projections of the prevalence of dementia in Japan: results from the Toyama Dementia Survey. BMC Geriatr. 2021;21:602.","journal-title":"BMC Geriatr"},{"key":"5982_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.14283\/jpad.2021.15","volume":"8","author":"XX Zhang","year":"2021","unstructured":"Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The epidemiology of Alzheimer\u2019s disease modifiable risk factors and prevention. J Prev Alzheimers Dis. 2021;8:313\u201321.","journal-title":"J Prev Alzheimers Dis"},{"key":"5982_CR9","unstructured":"Japanese Society of Neurology. Clinical practice guideline for dementia 2017. 2017. https:\/\/neurology-jp.org\/guidelinem\/dementia\/index.html. Accessed 30 Jul 2024."},{"key":"5982_CR10","unstructured":"United States Food and Drug Administration. FDA\u2019s decision to approve new treatment for Alzheimer\u2019s disease. 2021. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fdas-decision-approve-new-treatment-alzheimers-disease. Accessed 30 Jul 2024."},{"key":"5982_CR11","unstructured":"Biogen Inc. Biogen to realign resources for Alzheimer\u2019s disease franchise. 2024. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-realign-resources-alzheimers-disease-franchise. Accessed 1 Aug 2024."},{"key":"5982_CR12","unstructured":"United States Food and Drug Administration. FDA converts novel Alzheimer\u2019s disease treatment to traditional approval. 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. Accessed 30 Jul 2024."},{"key":"5982_CR13","unstructured":"EISAI Co., Ltd. \u201cLEQEMBI\u00ae intravenous infusion\u201d (Lecanemab) approved for the treatment of Alzheimer\u2019s disease in Japan. 2023. https:\/\/www.eisai.com\/news\/2023\/news202359.html?_gl=1*1griwks*_ga*MTI1MTg1NzUwMS4xNzA3ODk1ODg0*_ga_X1FWS6YR87*MTcxMDQ4OTE1MS4zLjEuMTcxMDQ4OTE4NC4yNy4wLjA. Accessed 30 Jul 2024."},{"key":"5982_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"5982_CR15","unstructured":"EISAI Co., Ltd. EISAI\u2019s approach to U.S. pricing for LEQEMBI\u2122 (LECANEMAB), a treatment for early Alzheimer\u2019s disease, sets forth our concept of \u201csocietal value of medicine\u201d in relation to \u201cprice of medicine\u201d. 2023. https:\/\/www.eisai.com\/news\/2023\/news202302.html. Accessed 30 Jul 2024."},{"key":"5982_CR16","doi-asserted-by":"publisher","first-page":"100657","DOI":"10.1016\/j.lanepe.2023.100657","volume":"29","author":"L J\u00f6nsson","year":"2023","unstructured":"J\u00f6nsson L, Wimo A, Handels R, Johansson G, Boada M, Engelborghs S, et al. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer\u2019s disease: an EADC-EC viewpoint. Lancet Reg Health Eur. 2023;29: 100657.","journal-title":"Lancet Reg Health Eur"},{"key":"5982_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/gps.4245","volume":"30","author":"K Deckers","year":"2015","unstructured":"Deckers K, van Boxtel MPJ, Schiepers OJG, de Vugt M, Mu\u00f1oz S\u00e1nchez JL, Anstey KJ, et al. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. Int J Geriatr Psychiatry. 2015;30:234\u201346.","journal-title":"Int J Geriatr Psychiatry"},{"key":"5982_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1186\/1471-2458-14-643","volume":"14","author":"MA Beydoun","year":"2014","unstructured":"Beydoun MA, Beydoun HA, Gamaldo AA, Teel A, Zonderman AB, Wang Y. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health. 2014;14:643.","journal-title":"BMC Public Health"},{"key":"5982_CR19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/0003-4819-153-3-201008030-00258","volume":"153","author":"BL Plassman","year":"2010","unstructured":"Plassman BL, Williams JW Jr, Burke JR, Holsinger T, Benjamin S. Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med. 2010;153:182\u201393.","journal-title":"Ann Intern Med"},{"key":"5982_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1365-2796.2010.02281.x","volume":"269","author":"F Sofi","year":"2011","unstructured":"Sofi F, Valecchi D, Bacci D, Abbate R, Gensini GF, Casini A, et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med. 2011;269:107\u201317.","journal-title":"J Intern Med"},{"key":"5982_CR21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/0010-4825(85)90073-3","volume":"15","author":"H Ogura","year":"1985","unstructured":"Ogura H, Sagara E, Yamamoto K, Furutani H, Kitazoe Y, Takeda Y. Analysis of the online order entry process in an integrated hospital information system. Comput Biol Med. 1985;15:381\u201393.","journal-title":"Comput Biol Med"},{"key":"5982_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10157-015-1156-5","volume":"20","author":"K Otomo","year":"2016","unstructured":"Otomo K, Horino T, Miki T, Kataoka H, Hatakeyama Y, Matsumoto T, et al. Serum uric acid level as a risk factor for acute kidney injury in hospitalized patients: a retrospective database analysis using the integrated medical information system at Kochi Medical School hospital. Clin Exp Nephrol. 2016;20:235\u201343.","journal-title":"Clin Exp Nephrol"},{"key":"5982_CR23","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1186\/s13104-019-4783-1","volume":"12","author":"S Watanabe","year":"2019","unstructured":"Watanabe S, Kawano T, Horino T, Matsumoto T, Nagata K, Hatakeyama Y, et al. Influence of hyperuricemia treatment on postoperative acute kidney injury among hyperuricemia patients: a single-center retrospective database analysis. BMC Res Notes. 2019;12:756.","journal-title":"BMC Res Notes"},{"key":"5982_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology"},{"key":"5982_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"5982_CR26","doi-asserted-by":"publisher","first-page":"e64933","DOI":"10.1371\/journal.pone.0064933","volume":"8","author":"GM Weber","year":"2013","unstructured":"Weber GM, Kohane IS. Extracting physician group intelligence from electronic health records to support evidence based medicine. PLoS ONE. 2013;8: e64933.","journal-title":"PLoS ONE"},{"key":"5982_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1479-8301.2012.00415.x","volume":"12","author":"C Ikejima","year":"2012","unstructured":"Ikejima C, Hisanaga A, Meguro K, Yamada T, Ouma S, Kawamuro Y, et al. Multicentre population-based dementia prevalence survey in Japan: a preliminary report. Psychogeriatrics. 2012;12:120\u20133.","journal-title":"Psychogeriatrics"},{"key":"5982_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41\u201355.","journal-title":"Biometrika"},{"key":"5982_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","volume":"82","author":"PR Rosenbaum","year":"1987","unstructured":"Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc. 1987;82:387\u201394.","journal-title":"J Am Stat Assoc"},{"key":"5982_CR30","first-page":"463","volume-title":"Bayesian statistics 2","author":"DB Rubin","year":"1985","unstructured":"Rubin DB. The use of propensity scores in applied Bayesian inference. In: Bernardo JM, DeGroot MH, Lindley DV, Smith AFM, editors. Bayesian statistics 2. North-Holland: Elsevier Science Publisher BV; 1985. p. 463\u201372."},{"key":"5982_CR31","unstructured":"R4.1.3 (R Core Team (2021). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021. URL https:\/\/www.R-project.org\/."},{"key":"5982_CR32","unstructured":"Greifer N. WeightIt: weighting for covariate balance in observational studies. R package version 0.13.1; 2022. https:\/\/CRAN.R-project.org\/package=WeightIt."},{"key":"5982_CR33","unstructured":"Greifer N. Cobalt: covariate balance tables and plots. R package version 4.3.2; 2022. https:\/\/CRAN.R-project.org\/package=cobalt."},{"key":"5982_CR34","unstructured":"World Health Organization. Serum and red blood cell folate concentrations for assessing folate status in populations. 2012.\u00a0https:\/\/iris.who.int\/bitstream\/handle\/10665\/75584\/WHO_NMH_NHD_EPG_12.1_eng.pdf?sequence=1. Accessed 19 Feb 2025."},{"key":"5982_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1527-3458.2002.tb00216.x","volume":"8","author":"K Nakamura","year":"2002","unstructured":"Nakamura K. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. CNS Drug Rev. 2002;8:70\u201389.","journal-title":"CNS Drug Rev"},{"key":"5982_CR36","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1248\/bpb.21.574","volume":"21","author":"K Ohtsuki","year":"1998","unstructured":"Ohtsuki K, Abe Y, Shimoyama Y, Furuya T, Munakata H, Takasaki C. Separation of phospholipase A2 in Habu snake venom by glycyrrhizin (GL)-affinity column chromatography and identification of a GL-sensitive enzyme. Biol Pharm Bull. 1998;21:574\u20138.","journal-title":"Biol Pharm Bull"},{"key":"5982_CR37","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s10787-021-00889-6","volume":"29","author":"R Dhapola","year":"2021","unstructured":"Dhapola R, Hota SS, Sarma P, Bhattacharyya A, Medhi B, Reddy DH. Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer\u2019s disease. Inflammopharmacology. 2021;29:1669\u201381.","journal-title":"Inflammopharmacology"},{"key":"5982_CR38","doi-asserted-by":"publisher","first-page":"1117172","DOI":"10.3389\/fimmu.2023.1117172","volume":"14","author":"C Wang","year":"2023","unstructured":"Wang C, Zong S, Cui X, Wang X, Wu S, Wang L, et al. The effects of microglia-associated neuroinflammation on Alzheimer\u2019s disease. Front Immunol. 2023;14:1117172.","journal-title":"Front Immunol"},{"key":"5982_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/nyas.13031","volume":"1367","author":"GE Gibson","year":"2016","unstructured":"Gibson GE, Hirsch JA, Fonzetti P, Jordan BD, Cirio RT, Elder J. Vitamin B1 (thiamine) and dementia. Ann N Y Acad Sci. 2016;1367:21\u201330.","journal-title":"Ann N Y Acad Sci"},{"key":"5982_CR40","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nature08538","volume":"461","author":"RJ Perrin","year":"2009","unstructured":"Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer\u2019s disease. Nature. 2009;461:916\u201322.","journal-title":"Nature"},{"key":"5982_CR41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.neurobiolaging.2010.03.011","volume":"33","author":"AJ Furst","year":"2012","unstructured":"Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A, Racine C, et al. Cognition, glucose metabolism and amyloid burden in Alzheimer\u2019s disease. Neurobiol Aging. 2012;33:215\u201325.","journal-title":"Neurobiol Aging"},{"key":"5982_CR42","unstructured":"Ministry of Internal Affairs and Communications. Population estimates (in Japanese, As of October 1, 2022). https:\/\/www.stat.go.jp\/data\/jinsui\/2022np\/pdf\/2022np.pdf. Accessed 7 Feb 2025."},{"key":"5982_CR43","unstructured":"Kochi Prefecture. Transportation Access (in Japanese). https:\/\/www.pref.kochi.lg.jp\/richi\/about\/access.html. Accessed 15 Feb 2025."},{"key":"5982_CR44","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic & Statistical Manual of Mental Disorders: DSM-5. Amer Psychiatric Pub Inc; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"5982_CR45","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cardfail.2017.04.007","volume":"23","author":"JA Cannon","year":"2017","unstructured":"Cannon JA, Moffitt P, Perez-Moreno AC, Walters MR, Broomfield NM, McMurray JJV, et al. Cognitive Impairment and Heart Failure: Systematic Review and Meta-Analysis. J Card Fail. 2017;23:464\u201375.","journal-title":"J Card Fail"},{"key":"5982_CR46","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrn3114","volume":"12","author":"BV Zlokovic","year":"2011","unstructured":"Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders. Nat Rev Neurosci. 2011;12:723\u201338.","journal-title":"Nat Rev Neurosci"},{"key":"5982_CR47","doi-asserted-by":"publisher","first-page":"e0161092","DOI":"10.1371\/journal.pone.0161092","volume":"11","author":"H Kazui","year":"2016","unstructured":"Kazui H, Yoshiyama K, Kanemoto H, Suzuki Y, Sato S, Hashimoto M, et al. Differences of Behavioral and Psychological Symptoms of Dementia in Disease Severity in Four Major Dementias. PLoS ONE. 2016;11: e0161092.","journal-title":"PLoS ONE"},{"key":"5982_CR48","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.3233\/JAD-201481","volume":"81","author":"J Hoffmann","year":"2021","unstructured":"Hoffmann J, Busse S, von Hoff F, Borucki K, Frodl T, Busse M. Association Between Homocysteine and Vitamin Levels in Demented Patients. J Alzheimers Dis. 2021;81:1781\u201392.","journal-title":"J Alzheimers Dis"},{"key":"5982_CR49","first-page":"CD004394","volume":"3","author":"R Malouf","year":"2003","unstructured":"Malouf R, Areosa Sastre A. Vitamin B12 for cognition. Cochrane Database Syst Rev. 2003;3:CD004394.","journal-title":"Cochrane Database Syst Rev."},{"key":"5982_CR50","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.mad.2017.10.001","volume":"174","author":"N Robinson","year":"2018","unstructured":"Robinson N, Grabowski P, Rehman I. Alzheimer\u2019s disease pathogenesis: Is there a role for folate? Mech Ageing Dev. 2018;174:86\u201394.","journal-title":"Mech Ageing Dev"},{"key":"5982_CR51","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3233\/JAD-150140","volume":"46","author":"L Shen","year":"2015","unstructured":"Shen L, Ji HF. Associations between Homocysteine, Folic Acid, Vitamin B12 and Alzheimer\u2019s Disease: Insights from Meta-Analyses. J Alzheimer\u2019s Dis. 2015;46:777\u201390.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"5982_CR52","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/ajcn\/82.3.636","volume":"82","author":"G Ravaglia","year":"2005","unstructured":"Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr. 2005;82:636\u201343.","journal-title":"Am J Clin Nutr"},{"key":"5982_CR53","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.psyneuen.2018.09.002","volume":"99","author":"P Quinlan","year":"2019","unstructured":"Quinlan P, Horvath A, Wallin A, Svensson J. Low serum concentration of free triiodothyronine (FT3) is associated with increased risk of Alzheimer\u2019s disease. Psychoneuroendocrinology. 2019;99:112\u20139.","journal-title":"Psychoneuroendocrinology"},{"key":"5982_CR54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12020-022-03190-w","volume":"79","author":"M Dolatshahi","year":"2023","unstructured":"Dolatshahi M, Salehipour A, Saghazadeh A, Sanjeari Moghaddam H, Aghamollaii V, Fotouhi A, et al. Thyroid hormone levels in Alzheimer disease: a systematic review and meta-analysis. Endocrine. 2023;79:252\u201372.","journal-title":"Endocrine"},{"key":"5982_CR55","doi-asserted-by":"publisher","first-page":"e0212261","DOI":"10.1371\/journal.pone.0212261","volume":"14","author":"E Begic","year":"2019","unstructured":"Begic E, Hadzidedic S, Kulaglic A, Ramic-Brkic B, Begic Z, Causevic M. SOMAscan-based proteomic measurements of plasma brain natriuretic peptide are decreased in mild cognitive impairment and in Alzheimer\u2019s dementia patients. PLoS ONE. 2019;14: e0212261.","journal-title":"PLoS ONE"},{"key":"5982_CR56","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1212\/WNL.0b013e318266fa70","volume":"79","author":"WT Hu","year":"2012","unstructured":"Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012;79:897\u2013905.","journal-title":"Neurology"},{"key":"5982_CR57","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/WNR.0b013e328326f82f","volume":"20","author":"D Kondziella","year":"2009","unstructured":"Kondziella D, G\u00f6thlin M, Fu M, Zetterberg H, Wallin A. B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia. NeuroReport. 2009;20:825\u20137.","journal-title":"NeuroReport"},{"key":"5982_CR58","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.exger.2013.12.001","volume":"50","author":"J Marksteiner","year":"2014","unstructured":"Marksteiner J, Imarhiagbe D, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C. Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer\u2019s disease and mild cognitive impairment: a pilot-study. Exp Gerontol. 2014;50:114\u201321.","journal-title":"Exp Gerontol"},{"key":"5982_CR59","doi-asserted-by":"publisher","first-page":"e011652","DOI":"10.1161\/JAHA.118.011652","volume":"8","author":"T Nagata","year":"2019","unstructured":"Nagata T, Ohara T, Hata J, Sakata S, Furuta Y, Yoshida D, et al. NT-proBNP and Risk of Dementia in a General Japanese Elderly Population: The Hisayama Study. J Am Heart Assoc. 2019;8: e011652.","journal-title":"J Am Heart Assoc"},{"key":"5982_CR60","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1021\/acschemneuro.9b00640","volume":"11","author":"YN Paudel","year":"2020","unstructured":"Paudel YN, Angelopoulou E, Semple B, Piperi C, Othman I, Shaikh MF. Potential neuroprotective effect of the HMGB1 inhibitor glycyrrhizin in neurological disorders. ACS Chem Neurosci. 2020;11:485\u2013500.","journal-title":"ACS Chem Neurosci"},{"key":"5982_CR61","unstructured":"Ministry of Health, Labor and Welfare. List of Drug Price Listings and Information on Generic Drugs: Injectable Drugs (in Japanese, effective February 1, 2025). 2025. https:\/\/www.mhlw.go.jp\/topics\/2024\/04\/dl\/tp20250201-01_02.pdf. Accessed 7 Feb 2025."},{"key":"5982_CR62","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1471-4159.2011.07581.x","volume":"120","author":"B Sheng","year":"2012","unstructured":"Sheng B, Wang X, Su B, Lee HG, Casadesus G, Perry G, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer\u2019s disease. J Neurochem. 2012;120:419\u201329.","journal-title":"J Neurochem"},{"key":"5982_CR63","doi-asserted-by":"publisher","first-page":"19318","DOI":"10.1073\/pnas.0804871105","volume":"105","author":"X Wang","year":"2008","unstructured":"Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission\/fusion proteins. Proc Natl Acad Sci U S A. 2008;105:19318\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5982_CR64","doi-asserted-by":"publisher","first-page":"9090","DOI":"10.1523\/JNEUROSCI.1357-09.2009","volume":"29","author":"X Wang","year":"2009","unstructured":"Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer\u2019s disease. J Neurosci. 2009;29:9090\u2013103.","journal-title":"J Neurosci"},{"key":"5982_CR65","doi-asserted-by":"publisher","first-page":"e35823","DOI":"10.1371\/journal.pone.0035823","volume":"7","author":"X Zhu","year":"2012","unstructured":"Zhu X, Chen C, Ye D, Guan D, Ye L, Jin J, et al. Diammonium glycyrrhizinate upregulates PGC-1\u03b1 and protects against A\u03b21-42-induced neurotoxicity. PLoS ONE. 2012;7: e35823.","journal-title":"PLoS ONE"},{"key":"5982_CR66","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.biocel.2004.07.009","volume":"37","author":"EE Tuppo","year":"2005","unstructured":"Tuppo EE, Arias HR. The role of inflammation in Alzheimer\u2019s disease. Int J Biochem Cell Biol. 2005;37:289\u2013305.","journal-title":"Int J Biochem Cell Biol"},{"key":"5982_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/cns.12043","volume":"19","author":"H Zhao","year":"2013","unstructured":"Zhao H, Wang SL, Qian L, Jin JL, Li H, Xu Y, et al. Diammonium glycyrrhizinate attenuates A\u03b21\u201342-induced neuroinflammation and regulates MAPK and NF-\u03baB pathways in vitro and in vivo. CNS Neurosci Ther. 2013;19:117\u201324.","journal-title":"CNS Neurosci Ther"},{"key":"5982_CR68","doi-asserted-by":"publisher","first-page":"31895","DOI":"10.1038\/srep31895","volume":"6","author":"K Fujita","year":"2016","unstructured":"Fujita K, Motoki K, Tagawa K, Chen X, Hama H, Nakajima K, et al. HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer\u2019s disease. Sci Rep. 2016;6:31895.","journal-title":"Sci Rep"},{"key":"5982_CR69","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s12031-017-0989-7","volume":"63","author":"ZH Kong","year":"2017","unstructured":"Kong ZH, Chen X, Hua HP, Liang L, Liu LJ. The oral pretreatment of glycyrrhizin prevents surgery-induced cognitive impairment in aged mice by reducing neuroinflammation and Alzheimer\u2019s-related pathology via HMGB1 inhibition. J Mol Neurosci. 2017;63:385\u201395.","journal-title":"J Mol Neurosci"},{"key":"5982_CR70","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s10571-012-9839-x","volume":"32","author":"M Tabuchi","year":"2012","unstructured":"Tabuchi M, Imamura S, Kawakami Z, Ikarashi Y, Kase Y. The blood-brain barrier permeability of 18\u03b2-glycyrrhetinic acid, a major metabolite of glycyrrhizin in Glycyrrhiza root, a constituent of the traditional Japanese medicine yokukansan. Cell Mol Neurobiol. 2012;32:1139\u201346.","journal-title":"Cell Mol Neurobiol"},{"key":"5982_CR71","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/jphp.13273","volume":"72","author":"JP Jourdan","year":"2020","unstructured":"Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. J Pharm Pharmacol. 2020;72:1145\u201351.","journal-title":"J Pharm Pharmacol"},{"key":"5982_CR72","unstructured":"Research project for the establishment of an NDB research system for health policy and other purposes through 6 NC collaboration. About the NDB. https:\/\/ndb6nc.ncgm.go.jp\/eng\/outline\/index.html. Accessed 30 Jul 2024."},{"key":"5982_CR73","unstructured":"Ministry of Health, Labor and Welfare. A manual for those considering using NDB (in Japanese). 2025. https:\/\/www.mhlw.go.jp\/content\/12400000\/001427722.pdf. Accessed 4 Mar 2025."},{"key":"5982_CR74","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejphar.2018.05.021","volume":"833","author":"Q Ge","year":"2018","unstructured":"Ge Q, Chen L, Tang M, Zhang S, Liu L, Gao L, et al. Analysis of mulberry leaf components in the treatment of diabetes using network pharmacology. Eur J Pharmacol. 2018;833:50\u201362.","journal-title":"Eur J Pharmacol"},{"key":"5982_CR75","first-page":"53","volume":"16","author":"XC Pang","year":"2018","unstructured":"Pang XC, Kang D, Fang JS, Zhao Y, Xu LJ, Lian WW, et al. Network pharmacology-based analysis of Chinese herbal Naodesheng formula for application to Alzheimer\u2019s disease. Chin J Nat Med. 2018;16:53\u201362.","journal-title":"Chin J Nat Med"},{"key":"5982_CR76","doi-asserted-by":"publisher","first-page":"e21800","DOI":"10.1016\/j.heliyon.2023.e21800","volume":"9","author":"M Zhang","year":"2023","unstructured":"Zhang M, Zheng H, He J, Zhang M. Network pharmacology and in vivo studies reveal the neuroprotective effects of paeoniflorin on Alzheimer\u2019s disease. Heliyon. 2023;9: e21800.","journal-title":"Heliyon"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-05982-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-025-05982-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-05982-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:03:47Z","timestamp":1746788627000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-025-05982-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5982"],"URL":"https:\/\/doi.org\/10.1186\/s12877-025-05982-x","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of Kochi Medical School approved the study protocol and waived the need for patient informed consent owing to the retrospective nature of the study (Reference Number: 2021\u201389). The study was conducted in accordance with the principles of the Declaration of Helsinki of 1975 (as amended in 1983).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"321"}}